MAX-40279

DB15191InvestigationalSmall molecule

MAX-40279 is under investigation in clinical trial NCT03412292 (MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3 and Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₂₂H₂₃FN₆OS · 438.53 g/mol (avg)
Code names: MAX-40279

Resolves to

Compound

Structure

InChIKeyAVIOBQFPAGEICQ-UHFFFAOYSA-NSMILESCOC1=CC(F)=CC=C1C1=C(C)SC2=CN=C(NC3=CN(N=C3)C3CCNCC3)N=C12

Targets

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with MAX-40279, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.